Literature DB >> 10037743

Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met.

R van der Voort1, T E Taher, V J Wielenga, M Spaargaren, R Prevo, L Smit, G David, G Hartmann, E Gherardi, S T Pals.   

Abstract

CD44 has been implicated in tumor progression and metastasis, but the mechanism(s) involved is as yet poorly understood. Recent studies have shown that CD44 isoforms containing the alternatively spliced exon v3 carry heparan sulfate side chains and are able to bind heparin-binding growth factors. In the present study, we have explored the possibility of a physical and functional interaction between CD44 and hepatocyte growth factor/scatter factor (HGF/SF), the ligand of the receptor tyrosine kinase c-Met. The HGF/SF-c-Met pathway mediates cell growth and motility and has been implicated in tumor invasion and metastasis. We demonstrate that a CD44v3 splice variant efficiently binds HGF/SF via its heparan sulfate side chain. To address the functional relevance of this interaction, Namalwa Burkitt's lymphoma cells were stably co-transfected with c-Met and either CD44v3 or the isoform CD44s, which lacks heparan sulfate. We show that, as compared with CD44s, CD44v3 promotes: (i) HGF/SF-induced phosphorylation of c-Met, (ii) phosphorylation of several downstream proteins, and (iii) activation of the MAP kinases ERK1 and -2. By heparitinase treatment and the use of a mutant HGF/SF with greatly decreased affinity for heparan sulfate, we show that the enhancement of c-Met signal transduction induced by CD44v3 was critically dependent on heparan sulfate moieties. Our results identify heparan sulfate-modified CD44 (CD44-HS) as a functional co-receptor for HGF/SF which promotes signaling through the receptor tyrosine kinase c-Met, presumably by concentrating and presenting HGF/SF. As both CD44-HS and c-Met are overexpressed on several types of tumors, we propose that the observed functional collaboration might be instrumental in promoting tumor growth and metastasis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10037743     DOI: 10.1074/jbc.274.10.6499

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  62 in total

Review 1.  Dysregulation of Met receptor tyrosine kinase activity in invasive tumors.

Authors:  Alla Danilkovitch-Miagkova; Berton Zbar
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

2.  CD44 is required for two consecutive steps in HGF/c-Met signaling.

Authors:  Véronique Orian-Rousseau; Linfeng Chen; Jonathan P Sleeman; Peter Herrlich; Helmut Ponta
Journal:  Genes Dev       Date:  2002-12-01       Impact factor: 11.361

Review 3.  Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression.

Authors:  Alessia Locatelli; Kristopher A Lofgren; Andrea R Daniel; Nancy E Castro; Carol A Lange
Journal:  Horm Cancer       Date:  2012-04       Impact factor: 3.869

Review 4.  Cancer stem cells: involvement in pancreatic cancer pathogenesis and perspectives on cancer therapeutics.

Authors:  Cristiana Pistol Tanase; Ana Iulia Neagu; Laura Georgiana Necula; Cristina Mambet; Ana-Maria Enciu; Bogdan Calenic; Maria Linda Cruceru; Radu Albulescu
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

5.  A positive feedback loop couples Ras activation and CD44 alternative splicing.

Authors:  Chonghui Cheng; Michael B Yaffe; Phillip A Sharp
Journal:  Genes Dev       Date:  2006-07-01       Impact factor: 11.361

6.  HIV-1 p17 matrix protein interacts with heparan sulfate side chain of CD44v3, syndecan-2, and syndecan-4 proteoglycans expressed on human activated CD4+ T cells affecting tumor necrosis factor alpha and interleukin 2 production.

Authors:  Maria A De Francesco; Manuela Baronio; Claudio Poiesi
Journal:  J Biol Chem       Date:  2011-04-11       Impact factor: 5.157

7.  Effects of hepatocyte growth factor/scatter factor on the invasion of colorectal cancer cells in vitro.

Authors:  Hong-Wu Li; Ji-Xian Shan
Journal:  World J Gastroenterol       Date:  2005-07-07       Impact factor: 5.742

Review 8.  CD44 in cancer progression: adhesion, migration and growth regulation.

Authors:  R Marhaba; M Zöller
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

Review 9.  MET as a target for treatment of chest tumors.

Authors:  Nicole A Cipriani; Oyewale O Abidoye; Everett Vokes; Ravi Salgia
Journal:  Lung Cancer       Date:  2008-07-30       Impact factor: 5.705

10.  Multiple osteochondromas: clinicopathological and genetic spectrum and suggestions for clinical management.

Authors:  Liesbeth Hameetman; Judith Vmg Bovée; Antonie Hm Taminiau; Herman M Kroon; Pancras Cw Hogendoorn
Journal:  Hered Cancer Clin Pract       Date:  2004-11-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.